J
John Fanikos
Researcher at Brigham and Women's Hospital
Publications - 150
Citations - 4084
John Fanikos is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Warfarin & Dabigatran. The author has an hindex of 34, co-authored 141 publications receiving 3305 citations. Previous affiliations of John Fanikos include MCPHS University & College of Health Sciences, Bahrain.
Papers
More filters
Journal ArticleDOI
Venous thromboembolic disease
Lawrence D. Wagman,Melissa F. Baird,Charles L. Bennett,Paula L. Bockenstedt,Spero R. Cataland,John Fanikos,Patrick F. Fogarty,Samuel Z. Goldhaber,Tejpal Grover,William Haire,Hani Hassoun,Suzanne Hutchinson,Mohammad Jahanzeb,Jason T. Lee,Michael L. Linenberger,Michael Millenson,Thomas L. Ortel,Riad Salem,Judy L. Smith,Michael B. Streiff,Suresh Vedantham +20 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
Journal ArticleDOI
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
Ann E. Woolley,Steve K. Singh,Hilary J. Goldberg,Hari R. Mallidi,Michael M. Givertz,Mandeep R. Mehra,Antonio Coppolino,Amanda E Kusztos,Megan E Johnson,Kaiwen Chen,Esther A Haddad,John Fanikos,David P. Harrington,Phillip C. Camp,Lindsey R. Baden,Donate Hcv Trial Team +15 more
TL;DR: In patients withoutHCV infection who received a heart or lung transplant from donors with hepatitis C viremia, treatment with an antiviral regimen for 4 weeks, initiated within a few hours after transplantation, prevented the establishment of HCV infection.
Journal ArticleDOI
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.
Gregory Piazza,Umberto Campia,Shelley Hurwitz,Julia E. Snyder,Samantha Rizzo,Mariana Pfeferman,Ruth B. Morrison,Orly Leiva,John Fanikos,Victor Nauffal,Zaid Almarzooq,Samuel Z. Goldhaber +11 more
TL;DR: Major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venousThromboEmbolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis.
Journal ArticleDOI
NCCN Guidelines® insights cancer-associated venous thromboembolic disease, version 2.2018 featured updates to the NCCN guidelines
Michael B. Streiff,Bjorn Holmstrom,Dana Angelini,Aneel A. Ashrani,Paula L. Bockenstedt,Carolyn M. Chesney,John Fanikos,Randolph B. Fenninger,Annemarie E. Fogerty,Shuwei Gao,Samuel Z. Goldhaber,Krishna Gundabolu,Paul C. Hendrie,Alfred Lee,Jason T. Lee,Janelle Mann,Brandon McMahon,Michael Millenson,Colleen Morton,Thomas L. Ortel,Sadat Ozair,Rita Paschal,Sanford J. Shattil,Tanya Siddiqi,Kristi J. Smock,Gerald A. Soff,Tzu-Fei Wang,Eliot C. Williams,Anaadriana Zakarija,Lydia J. Hammond,Mary A. Dwyer,Anita M. Engh +31 more
TL;DR: The NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.
Journal ArticleDOI
Predictors of Major Hemorrhage Following Fibrinolysis for Acute Pulmonary Embolism
TL;DR: One hundred four patients at Brigham and Women's Hospital who received alteplase for acute pulmonary embolism were evaluated and independent predictors of major hemorrhage were the administration of catecholamines for systemic arterial hypotension and elevated international normalized ratio before fibrinolysis.